je.st
news
Home
› Syros Pharmaceuticals Announces FDA Acceptance Of IND To Advance SY-1425 Into Phase 2 Clinical Trial
Syros Pharmaceuticals Announces FDA Acceptance Of IND To Advance SY-1425 Into Phase 2 Clinical Trial
2016-06-01 04:49:19| drugdiscoveryonline Home Page
Syros Pharmaceuticals recently announced that the U.S. Food and Drug Administration (FDA) accepted the Company’s Investigational New Drug (IND) application to advance its lead drug candidate, SY-1425, a potent and selective retinoic acid receptor alpha (RARα) agonist, into a Phase 2 clinical trial in genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia (AML) and relapsed high-risk myelodysplastic syndrome (MDS) identified through its platform
Tags: trial
advance
phase
acceptance
Category:Biotechnology and Pharmaceuticals